CONTACT KTMC

Investor Class Action Filed Against Alnylam Pharmaceuticals, Inc. for Securities Fraud Violations
Company Name: Alnylam Pharmaceuticals, Inc.
Court: United States District Court for the District of Massachusetts
Case Number: 18-cv-12433
Judge: The Hon. Nathaniel M. Gorton
Class period: Between September 20, 2017 and September 12, 2018
Security Type: Securities

Case Background:

On September 26, 2018, the initial complaint in this securities class action was filed against Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”), and certain of Alnylam’s directors and officers, asserting violations of sections 10(b) and 20(a) of the Securities Exchange Act.  

The complaint alleged that throughout the class period, the defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, the complaint alleged that the defendants made false and/or misleading statements and/or failed to disclose that: (i) Alnylam overstated the efficacy and safety of its Onpattro (patisiran) lipid complex injection; and (ii) as a result, Alnylam’s public statements were materially false and misleading at all relevant times.

This securities class action lawsuit was brought on behalf of all persons or entities who purchased or otherwise acquired Alnylam securities between September 20, 2017 and September 12, 2018, inclusive.

Current Status of Case:

On March 23, 2020, the Court granted the defendants' motion to dismiss the lead plaintiff’s amended complaint. On June 1, 2020, the lead plaintiff filed a motion for leave to file a second amended complaint.  The defendants filed an opposition to this motion on June 15, 2020.  The motion for leave to file a second amended complaint is now fully briefed before the Court pending its decision.  This action is still ongoing.

If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.

CONTACT:
Kessler Topaz Meltzer & Check, LLP
James Maro, Esq. or Adrienne Bell, Esq.
280 King of Prussia Road
Radnor, PA 19087 1-844-887-9500 (toll free) or 1-610-667-7706
Or by e-mail at info@ktmc.com

Please complete this form relating to your transactions for Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) securities between between September 20, 2017 and September 12, 2018, both dates inclusive (the “Class Period”).

You may also contact James Maro, Jr., Esq. or Adrienne Bell, Esq. at 610.667.7706 or toll free at 844.887.9500, or you may submit your information via email at info@ktmc.com, or you may click here to print a PDF of this form.

* Denotes required field
 
 
 
 
 
 
# of Shares
Price per Share
 
 
 
Principal Amount
Amount Paid
Series or CUSIP
 
 
 
# of Contracts
Price per Contract
Exercise Price
Expiration Date
Did you purchase shares of Alnylam Pharmaceuticals, Inc. (2018) prior to the Class Period?
Are you a current or former employee of Alnylam Pharmaceuticals, Inc. (2018)?
The submission of this form does not create an attorney-client relationship, nor an obligation on the part of Kessler Topaz or you to file a lead plaintiff motion in this matter. Any information you submit will be maintained as confidential. If Kessler Topaz, in its sole discretion, believes that you might be an appropriate lead plaintiff candidate, Kessler Topaz will contact you to discuss the matter and whether to establish an attorney client relationship. By signing this form you are authorizing us to contact you regarding this case and/or future cases.
I agree to the KTMC
disclaimer
I would like to receive
new case alerts by email